

Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 study

Lisanne van Prooyen Schuurman, Erik A. Sistermans, Diane Van Opstal, Lidewij Henneman, Mireille N. Bekker, Caroline J. Bax, Mijntje J. Pieters, Katelijne Bouman, Sonja de Munnik, Nicolette S. den Hollander, Karin E.M. Diderich, Brigitte H.W. Faas, Ilse Feenstra, Attie T.J.I. Go, Mariëtte J.V. Hoffer, Marieke Joosten, Fenne L. Komdeur, Klaske D. Lichtenbelt, Maria P. Lombardi, Marike G. Polak, Fernanda S. Jehee, Heleen Schuring-Blom, Servi J.C. Stevens, Malgorzata I. Srebniak, Ron F. Suijkerbuijk, Gita M. Tan-Sindhunata, Karuna R.M. van der Meij, Merel C. van Maarle, Vivian Vernimmen, Shama L. van Zelderen-Bhola, Nicolien T. van Ravesteyn, Maarten F.C.M. Knapen, Merryn V.E. Macville, Robert-Jan H. Galjaard,* and The Dutch NIPT consortium

(The American Journal of Human Genetics 109, 1140–1152; June 2, 2022)

In the originally published version of this article, in Table 3, the column heading “Placenta biopsies” was placed erroneously under “Available clinical follow-up” instead of under “Available cytogenic follow-up.” The authors apologize for this error, which has been corrected online.

*Correspondence: r.galjaard@erasmusmc.nl
<https://doi.org/10.1016/j.ajhg.2022.06.003>.

© 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

